Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs

Marianne Abifadel, Sandy Elbitar, Petra EL Khoury, Youmna Ghaleb, Melody El Chemaly, Marie-Line Moussalli, Jean-Pierre Rabes, Mathilde Varret, Catherine Boileau

Research output: Contribution to journalReview article

59 Citations (Scopus)

Abstract

A decade after our discovery of the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in cholesterol metabolism through the identification of the first mutations leading to hypercholesterolemia, PCSK9 has become one of the most promising targets in cholesterol and cardiovascular diseases. This challenging work in the genetics of hypercholesterolemia paved the way for a plethora of studies around the world allowing the characterization of PCSK9, its expression, its impact on reducing the abundance of LDL receptor, and the identification of loss-of-function mutations in hypocholesterolemia. We highlight the different steps of this adventure and review the published clinical trials especially those with the anti-PCSK9 antibodies evolocumab (AMG 145) and alirocumab (SAR236553/REGN727), which are in phase III trials. The promising results in lowering LDL cholesterol levels raise hope that the PCSK9 adventure will lead, after the large and long-term ongoing phase III studies evaluating efficacy and safety, to a new anticholesterol pharmacological class.
LanguageEnglish
Article number16:439
Number of pages23
JournalCurrent Atherosclerosis Reports
Issue number439
Early online date23 Jul 2014
DOIs
Publication statusPublished - Sep 2014

Fingerprint

Hyperlipoproteinemia Type II
Pharmaceutical Preparations
Genes
Hypercholesterolemia
Cholesterol
Mutation
LDL Receptors
LDL Cholesterol
Cardiovascular Diseases
Proprotein Convertase 9
Clinical Trials
Pharmacology
Safety
Antibodies

Keywords

  • Hypercholesterolemia
  • LDLR
  • PCSK9
  • Gain of function mutations
  • Loss of function
  • Evolocumab
  • Alirocumab

Cite this

Abifadel, Marianne ; Elbitar, Sandy ; EL Khoury, Petra ; Ghaleb, Youmna ; El Chemaly, Melody ; Moussalli, Marie-Line ; Rabes, Jean-Pierre ; Varret, Mathilde ; Boileau, Catherine. / Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs. In: Current Atherosclerosis Reports. 2014 ; No. 439.
@article{c1477b208b2a46c498202718897c8af7,
title = "Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs",
abstract = "A decade after our discovery of the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in cholesterol metabolism through the identification of the first mutations leading to hypercholesterolemia, PCSK9 has become one of the most promising targets in cholesterol and cardiovascular diseases. This challenging work in the genetics of hypercholesterolemia paved the way for a plethora of studies around the world allowing the characterization of PCSK9, its expression, its impact on reducing the abundance of LDL receptor, and the identification of loss-of-function mutations in hypocholesterolemia. We highlight the different steps of this adventure and review the published clinical trials especially those with the anti-PCSK9 antibodies evolocumab (AMG 145) and alirocumab (SAR236553/REGN727), which are in phase III trials. The promising results in lowering LDL cholesterol levels raise hope that the PCSK9 adventure will lead, after the large and long-term ongoing phase III studies evaluating efficacy and safety, to a new anticholesterol pharmacological class.",
keywords = "Hypercholesterolemia, LDLR , PCSK9, Gain of function mutations, Loss of function, Evolocumab, Alirocumab",
author = "Marianne Abifadel and Sandy Elbitar and {EL Khoury}, Petra and Youmna Ghaleb and {El Chemaly}, Melody and Marie-Line Moussalli and Jean-Pierre Rabes and Mathilde Varret and Catherine Boileau",
year = "2014",
month = "9",
doi = "10.1007/s11883-014-0439-8",
language = "English",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
number = "439",

}

Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs. / Abifadel, Marianne ; Elbitar, Sandy; EL Khoury, Petra; Ghaleb, Youmna; El Chemaly, Melody; Moussalli, Marie-Line; Rabes, Jean-Pierre; Varret, Mathilde; Boileau, Catherine.

In: Current Atherosclerosis Reports, No. 439, 16:439, 09.2014.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs

AU - Abifadel, Marianne

AU - Elbitar, Sandy

AU - EL Khoury, Petra

AU - Ghaleb, Youmna

AU - El Chemaly, Melody

AU - Moussalli, Marie-Line

AU - Rabes, Jean-Pierre

AU - Varret, Mathilde

AU - Boileau, Catherine

PY - 2014/9

Y1 - 2014/9

N2 - A decade after our discovery of the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in cholesterol metabolism through the identification of the first mutations leading to hypercholesterolemia, PCSK9 has become one of the most promising targets in cholesterol and cardiovascular diseases. This challenging work in the genetics of hypercholesterolemia paved the way for a plethora of studies around the world allowing the characterization of PCSK9, its expression, its impact on reducing the abundance of LDL receptor, and the identification of loss-of-function mutations in hypocholesterolemia. We highlight the different steps of this adventure and review the published clinical trials especially those with the anti-PCSK9 antibodies evolocumab (AMG 145) and alirocumab (SAR236553/REGN727), which are in phase III trials. The promising results in lowering LDL cholesterol levels raise hope that the PCSK9 adventure will lead, after the large and long-term ongoing phase III studies evaluating efficacy and safety, to a new anticholesterol pharmacological class.

AB - A decade after our discovery of the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in cholesterol metabolism through the identification of the first mutations leading to hypercholesterolemia, PCSK9 has become one of the most promising targets in cholesterol and cardiovascular diseases. This challenging work in the genetics of hypercholesterolemia paved the way for a plethora of studies around the world allowing the characterization of PCSK9, its expression, its impact on reducing the abundance of LDL receptor, and the identification of loss-of-function mutations in hypocholesterolemia. We highlight the different steps of this adventure and review the published clinical trials especially those with the anti-PCSK9 antibodies evolocumab (AMG 145) and alirocumab (SAR236553/REGN727), which are in phase III trials. The promising results in lowering LDL cholesterol levels raise hope that the PCSK9 adventure will lead, after the large and long-term ongoing phase III studies evaluating efficacy and safety, to a new anticholesterol pharmacological class.

KW - Hypercholesterolemia

KW - LDLR

KW - PCSK9

KW - Gain of function mutations

KW - Loss of function

KW - Evolocumab

KW - Alirocumab

UR - https://link.springer.com/article/10.1007%2Fs11883-014-0439-8

U2 - 10.1007/s11883-014-0439-8

DO - 10.1007/s11883-014-0439-8

M3 - Review article

JO - Current Atherosclerosis Reports

T2 - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 439

M1 - 16:439

ER -